drugset / Trial / NCT06207877

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

NCT06207877

Phase 1 Completed 62 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on the body. The treatment participants get is decided by chance. The study will last for about 32 weeks.

Timeline

Start
2024-02-23
Primary completion
2024-10-16
Completion
2024-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Cagrilintide Protein / enzyme biologic Subcutaneous
Subject Semaglutide Peptide Subcutaneous

Indications